Cappella, a developer of dynamic solutions for the treatment of coronary bifurcation diseases, has presented a serial IVUS analysis and Sideguard 3.25 device during the Joint Interventional Meeting (JIM) in Rome.
Gary Mintz of Cardiovascular Research Foundation, New York, US, has presented study entitled ‘Positive Vessel Remodeling Using Sideguard in Coronary Bifurcations’ during the New Technologies Symposium. Dr Mintz has reported that serial IVUS and OCT are ongoing in the Sideguard 3 study to confirm the initial findings of Sideguard and assess stent strut coverage. The IVUS sub-study results from Sideguard were published in the American Journal of Cardiology in October 2009.
Reportedly, the new addition to the Sideguard portfolio, the Sideguard 3.25, has been implanted successfully in a case performed by Ralf Mueller, MD, Siegburg, Germany.
Cappella’s initial product, the Sideguard coronary sidebranch stent and delivery system offers interventional cardiologists a solution that focuses on treating the sidebranch of diseased coronary arteries first, rather than the main vessel. It allows the preferred stent of choice for the main vessel. An optimal stent design specific to the anatomy of the sidebranch, combined with the qualities of Nitinol provide a solution for treating sidebranch disease.
Dr Mueller, said: “We implanted the Sideguard 3.25 stent together with a 3,0mm DES in a Medina 0,1,1 LAD/D1 stenosis. Positioning was easy and precise and IVUS demonstrated excellent scaffolding at the bifurcation. The use of the Sideguard device made this bifurcation intervention easy and predictable with an optimal acute result.”
Martin Leon, founder and director of Transcatheter Cardiovascular Therapeutics (TCT) and Scientific Advisory Board member of Cappella assisted with the case. Dr Leon expressed his satisfaction with the device, said: “It was the first time I used the 3.25 and I was very pleased with the outcome of the case.”